LXEO
Lexeo Therapeutics Inc.

561
Mkt Cap
$727.23M
Volume
1.32M
52W High
$10.56
52W Low
$1.45
PE Ratio
-3.69
LXEO Fundamentals
Price
$10.54
Prev Close
$9.96
Open
$10.10
50D MA
$9.18
Beta
1.95
Avg. Volume
1.39M
EPS (Annual)
-$3.09
P/B
4.53
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Frazier Life Sciences Management L.P. Has $17.79 Million Position in Lexeo Therapeutics, Inc. $LXEO
Frazier Life Sciences Management L.P. lifted its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 363.1% in the 2nd quarter, according to the company in its most recent disclosure...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Lexeo Therapeutics' (LXEO) Buy Rating Reaffirmed at Chardan Capital
Chardan Capital reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Thursday...
MarketBeat·8d ago
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 7.8% - What's Next?
Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 7.8% - Here's What Happened...
MarketBeat·17d ago
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) Now Covered by Analysts at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage on shares of Lexeo Therapeutics in a research note on Monday. They set an "overweight" rating and a $19.00 target price for the company...
MarketBeat·17d ago
News Placeholder
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 1,127 Shares of Stock
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 1,127 shares of the company's stock in a transaction that occurred on Tuesday, November 18th. The stock was...
MarketBeat·28d ago
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated at Cantor Fitzgerald
Cantor Fitzgerald started coverage on shares of Lexeo Therapeutics in a research report on Thursday. They set an "overweight" rating and a $19.00 price target for the company...
MarketBeat·28d ago
News Placeholder
Equities Analysts Set Expectations for LXEO FY2025 Earnings
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for Lexeo Therapeutics in a note issued to investors on...
MarketBeat·29d ago
News Placeholder
Wall Street Analysts Predict a 124.3% Upside in Lexeo Therapeutics, Inc. (LXEO): Here's What You Should Know
The consensus price target hints at a 124.3% upside potential for Lexeo Therapeutics, Inc. (LXEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·1mo ago
News Placeholder
Research Analysts Set Expectations for LXEO FY2025 Earnings
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities researchers at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Lexeo Therapeutics in a report...
MarketBeat·1mo ago
News Placeholder
Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) released its earnings results on Wednesday. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by...
MarketBeat·1mo ago
<
1
2
...
>

Latest LXEO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.